|
“PHYSICIANS are allowed to dispense and maintain an
appropriate amount of dangerous drugs, provided they
don’t have access to commercial drugstores within 5
kilometers from their location.”
This was
revealed by Belen Matibag, deputy executive director for
operations of the Dangerous Drugs Board (DDB), during
their Technical Working Group (TWG) meeting on the
“Classification of Dangerous Drugs, Controlled
Precursors and Essential Chemicals late last week.
Earlier,
physicians from various hospitals in Metro Manila
disclosed their practice of administering regulated
drugs directly to their patients.
The
group reviewed the salient points of Board Regulation 3,
Series of 2000 and Board Regulation 3, Series of 2003.
Both provide specific directives on the dispensing and
prescribing of dangerous drugs, and covers physicians,
dentists, chemists, medical technologists, nurses,
midwives and veterinarians.
Physicians who have S-2 licenses are allowed to maintain
a “professional supply” of dangerous drugs and similar
preparations, provided that they would maintain a record
of receipt and distribution of such substances. More so,
they are to submit these registers for review of the
DDB, through the Philippine Drug Enforcement Agency.
Those
who are, however, located in areas with ready access to
drugstores and hospitals that dispense dangerous drugs
and related drug preparations will not be allowed to
dispense and maintain supply of such substances.
Matibag
cited that this move to observe legal procedures is in
line with one of the DDB’s aims to streamline legal
medical operations by harmonizing enforcement with that
of ready access of legitimate users to dangerous drugs.
The
logic of this practice said Allan Dionisio of the
National Poison Management Control Center and TWG
member, is that it balances two values—one is preventing
diversion of dangerous drugs to the illegal market; and
second, ensuring that due treatment reaches those
patients who need these drugs.
While
certain drugs classified as dangerous by Republic Act
9165, otherwise known as the Comprehensive Dangerous
Drugs Act of 2002, and by the DDB have therapeutic value
and are helpful in pain management, they remain to be
highly regulated, since they stimulate psychoactive
effects, have high potential for abuse and are prone to
diversion, Matibag said.
The DDB,
as the policy-making and strategy-formulating body on
matters of drug abuse prevention and control, employs
regulatory compliance under its drug supply reduction
strategy. The legitimate users of these substances are
assured of access to these drugs and at the same time,
abuse and diversion of such to the illicit market is
stopped. |